2025-11-23 - Analysis Report
Okay, here's an analysis of Natera (NTRA) based on the data you provided.

## Natera (NTRA) Stock Analysis

**Ticker:** NTRA
**Company Name:** Natera Inc.
**Description:** Natera is a diagnostics company focusing on cell-free DNA testing for reproductive health, oncology, and organ health.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 137.41%
*   **VOO Cumulative Return:** 95.46%
*   **Absolute Deviation:** 41.95%
*   **Relative Deviation:** 38.0 (On a scale where the historical range of difference between NTRA and VOO is normalized to 100, the current deviation sits at the 38th percentile.)

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) in terms of cumulative return. However, the relative deviation indicates that the current outperformance is not at its historical peak (38th percentile), suggesting that the stock's performance relative to VOO could still have potential for further gains.

### Alpha, Beta Analysis

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| :----------- | :----- | :----- | :------ | :---- | :----- |
| 2015-2017  | -10.0% | 70.1% | -34.0%  | -0.0  | 1.2    |
| 2016-2018  | 22.0%  | 80.0% | 6.0%   | 0.0   | 1.9    |
| 2017-2019  | 50.0%  | 80.0% | 28.0%  | 1.1   | 4.7    |
| 2018-2020  | 186.0% | 80.5% | 163.0% | 1.2   | 13.7   |
| 2019-2021  | 96.0%  | 80.5% | 49.0%  | 1.6   | 12.9   |
| 2020-2022  | -77.0% | 80.5% | -76.0%  | 0.1   | 5.5    |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1  | 8.7    |
| 2022-2024  | 8.0%   | 76.6% | -13.0%  | -1.2  | 21.9   |
| 2023-2025  | 164.0% | 76.6% | 105.0% | 0.1   | 31.8   |

*   **CAGR:** Fluctuates significantly, showing high volatility in returns.
*   **MDD:** Consistently high, indicating substantial downside risk.
*   **Alpha:** Highly variable, with periods of significant outperformance and underperformance relative to the market.
*   **Beta:** Generally close to 1, suggesting market-like sensitivity. More recent periods show negative beta, indicating potential for gains when the market declines.
*   **Cap(B):** Market capitalization has grown significantly over time.

**Analysis:** This data reveals a high-risk, high-reward profile. While NTRA has demonstrated periods of exceptional growth (high CAGR and Alpha), it also experiences substantial drawdowns. The Beta values suggest that the stock has become less correlated with the overall market recently.

### 2. Recent Price Action

*   **Current Price:** $230.63
*   **Previous Close:** $225.55
*   **Change:** 2.25%
*   **5-day Moving Average:** $218.84
*   **20-day Moving Average:** $204.34
*   **60-day Moving Average:** $183.40

**Analysis:** The price is above all three moving averages, indicating a strong uptrend.  The positive change from the previous close and the relatively large percentage increase (2.25%) indicates strong recent momentum.

### 3. Indicators and Expected Return

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 80.60 (Overbought)
*   **PPO:** 0.8187
*   **Hybrid Signal:** Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence (20-day):** 1.7 (+) - Short-term increase
*   **Expected Return:** -75.2% (Long-term relative to S&P 500)

**Analysis:**

*   The RSI suggests the stock is currently overbought, which could indicate a potential pullback in the short term.
*   The PPO indicates positive momentum.
*   The recent increase in relative divergence suggests short-term upward movement.
*   The large 2.25% price increase from the previous close suggests a recent positive event driving the stock.
*   The negative expected return (-75.2%) suggests that, based on the model, NTRA is expected to significantly underperform the S&P 500 over the long term. This is a concerning signal for long-term investors.
*   The MRI indicates Medium Investment, while the Hybrid Signal is recommending a buy. These two signals suggest the investment is appropriate, but care should be taken.

### 4. Recent News & Significant Events

*   **Positive Headlines:** Several articles highlight Natera's potential, including Flatiron Health integration and inclusion in lists of promising stocks. The UBS price target increase to $280 reinforces positive sentiment.
*   **Cathie Wood's Actions:** News that Cathie Wood dumped AMD might suggest a shift toward other tech/healthcare stocks like Natera, although the direct link isn't explicitly stated.
*   **Employee Volunteerism:** While positive for corporate image, this is unlikely to have a significant impact on stock price.

**Analysis:** Recent news is overwhelmingly positive, with analyst upgrades, inclusion in "winner" lists, and potential expansion of market opportunity. This likely contributed to the recent price surge.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy (1.47)
*   **Target Price:** $234.16 (Average) / $280 (High) / $186 (Low)

**Analysis:** Analyst consensus is strongly positive, with an average target price slightly above the current price. The high target price of $280 suggests significant upside potential.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue        |
| :---------- | :---- | :------------- |
| 2025-11-07 | -0.64 | 0.59 B$        |
| 2025-08-08 | -0.74 | 0.55 B$        |
| 2025-05-09 | -0.5  | 0.50 B$        |
| 2024-11-12 | -0.26 | 0.44 B$        |
| 2025-11-07 | -0.26 | 0.44 B$        |

**Analysis:** While revenue is generally increasing, EPS remains negative, indicating the company is not yet profitable. The most recent EPS of -0.64 is concerning, and the re-listing of data of 2024-11-12 is suspicious.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
| :--------- | :------- | :------ |
| 2025-09-30 | $1.25B  | -6.99% |
| 2025-06-30 | $1.25B  | -8.10% |
| 2025-03-31 | $1.24B  | -5.40% |
| 2024-12-31 | $1.20B  | -4.50% |
| 2024-09-30 | $0.88B  | -3.60% |

**Analysis:**

*   Revenue is steadily increasing, and profit margins are healthy and expanding.
*   Equity is growing, suggesting the company is reinvesting profits.
*   ROE remains negative, reflecting the ongoing lack of profitability, but has shown an improvement.

### 7. Overall Summary

Natera (NTRA) presents a mixed picture.

*   **Positives:**
    *   Strong historical outperformance vs. the S&P 500.
    *   Strong recent price momentum and positive news flow.
    *   High revenue growth and improving profit margins.
    *   Strong analyst consensus.
*   **Negatives:**
    *   High historical volatility and MDD.
    *   Overbought RSI.
    *   Consistently negative EPS and ROE, indicating lack of current profitability.
    *   Very negative expected return based on the provided model.

**Conclusion:**

NTRA is a growth stock with significant potential but also considerable risk. The recent positive momentum and analyst sentiment are encouraging, but the lack of profitability and negative expected return are significant concerns. The overbought RSI suggests a potential short-term pullback.

**Recommendation:**

Given the high-risk profile, NTRA is best suited for investors with a high-risk tolerance and a long-term investment horizon who believe in the company's long-term growth potential. A cautious approach is warranted, with close monitoring of earnings reports and news flow. Consider taking partial profits if the stock reaches analyst target prices. It is important to do further due diligence and consider your own financial situation and risk tolerance before making any investment decisions. The MRI rating of Medium Investment suggests the investment may be worth it.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice.
